Founder
BostonGene
BostonGene utilizes an AI-powered multi-omics platform to perform molecular and immune profiling, enabling precise therapy matching for patients with cancer and immune-related diseases. This approach identifies actionable mutations and biomarkers, generating personalized treatment roadmaps that enhance clinical decision-making and improve patient outcomes.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$320MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Cancer treatment is often hindered by a lack of comprehensive understanding of the unique genomic and immune characteristics of each patient's tumor. This incomplete information can lead to suboptimal treatment choices, reduced therapy response, and increased risk of disease progression.
Solution
BostonGene provides an AI-powered platform that performs multi-omic molecular and immune profiling to enable personalized therapy matching for cancer and immune-related diseases. The platform analyzes tumor tissue and normal samples using advanced DNA and RNA sequencing to identify actionable mutations, biomarkers, and microenvironment properties. This comprehensive analysis generates a personalized treatment roadmap, providing clinicians with insights to enhance clinical decision-making, improve therapy response rates, and reduce the risk of disease progression. The BostonGene Tumor Portrait™ test delivers a holistic 360° overview of each cancer patient, integrating genomic alterations, tumor microenvironment analysis, and potential treatment options.
Target Audience
The primary target audience includes oncologists, pathologists, and biopharmaceutical companies seeking to improve cancer treatment through personalized medicine and accelerate drug development.
Features
- Whole exome and transcriptome sequencing to detect all relevant genomic alterations
- Liquid biopsy for comprehensive genomic profiling when tissue testing is not an option
- Immune system profiling to identify hundreds of different cell types from a single tube of blood
- Proprietary AI-driven platform that integrates advanced bioinformatics and multiomic analytics
- Identification of clinically actionable biomarkers, including PD-L1 and MMR
- Analysis of the tumor microenvironment to predict prognosis and immunotherapy response
- Matching of patients to clinical trials based on their unique genomic profile
- Digital pathology for AI-based analysis of tissue samples